Literature DB >> 19031026

T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.

David J Kahler1, Andrew L Mellor.   

Abstract

Mature dendritic cells (DCs) are potent stimulators of T cells that recognize antigens presented by the DCs. In this chapter we describe mature DCs that suppress T cell responses to antigens they present due to expression of the intracellular enzyme indoleamine 2,3 dioxygenase (IDO). IDO-competent DCs are a subset of plasmacytoid DCs that can be induced to express IDO under certain inflammatory conditions in humans and mice. Though rare, IDO-expressing DCs acquire potent T cell suppressor activity that may predominate over the T cell stimulatory functions of all other antigen-presenting cells in physiologic environments due in part, to cooperation with regulatory T cells. Thus, IDO-expressing DCs are critical regulators of adaptive immunity that contribute to a wide range of inflammatory disease processes. As such, manipulating IDO expression in DCs using IDO inhibitors or IDO inducers offers considerable opportunities to improve immunotherapies in a range of clinically-significant disease syndromes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19031026      PMCID: PMC5698849          DOI: 10.1007/978-3-540-71029-5_8

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  142 in total

1.  CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells.

Authors:  U Grohmann; F Fallarino; S Silla; R Bianchi; M L Belladonna; Carmine Vacca; A Micheletti; M C Fioretti; P Puccetti
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

2.  Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12.

Authors:  Ciriana Orabona; Elena Tomasello; Francesca Fallarino; Roberta Bianchi; Claudia Volpi; Silvia Bellocchio; Luigina Romani; Maria C Fioretti; Eric Vivier; Paolo Puccetti; Ursula Grohmann
Journal:  Eur J Immunol       Date:  2005-11       Impact factor: 5.532

3.  1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity.

Authors:  Sophie Agaugué; Laure Perrin-Cocon; Frédéric Coutant; Patrice André; Vincent Lotteau
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

4.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

5.  Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate.

Authors:  S R Thomas; H Salahifar; R Mashima; N H Hunt; D R Richardson; R Stocker
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

6.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

Review 7.  Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism.

Authors:  M W Taylor; G S Feng
Journal:  FASEB J       Date:  1991-08       Impact factor: 5.191

8.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

9.  IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells.

Authors:  Marcelo Hill; Séverine Tanguy-Royer; Pierre Royer; Christine Chauveau; Kashif Asghar; Laurent Tesson; Frédéric Lavainne; Séverine Rémy; Régis Brion; François-Xavier Hubert; Michèle Heslan; Marie Rimbert; Laureline Berthelot; John R Moffett; Régis Josien; Marc Grégoire; Ignacio Anegon
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

10.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase.

Authors:  Hiroshi Sugimoto; Shun-ichiro Oda; Takashi Otsuki; Tomoya Hino; Tadashi Yoshida; Yoshitsugu Shiro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more
  13 in total

1.  Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients.

Authors:  Amena W Smith; Bently P Doonan; William R Tyor; Nada Abou-Fayssal; Azizul Haque; Naren L Banik
Journal:  J Neuroimmunol       Date:  2010-11-13       Impact factor: 3.478

2.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

Review 3.  Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege.

Authors:  Lei Huang; Babak Baban; Burles A Johnson; Andrew L Mellor
Journal:  Int Rev Immunol       Date:  2010-04       Impact factor: 5.311

4.  Whole genome response in guinea pigs infected with the high virulence strain Mycobacterium tuberculosis TT372.

Authors:  Mohamed Aiyaz; Chand Bipin; Vinay Pantulwar; Raja Mugasimangalam; Crystal A Shanley; Diane J Ordway; Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2014-12       Impact factor: 3.131

5.  Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO).

Authors:  Juliana Croitoru-Lamoury; Francois M J Lamoury; Michael Caristo; Kazuo Suzuki; David Walker; Osamu Takikawa; Rosanne Taylor; Bruce J Brew
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

6.  Lipopolysaccharide-pretreated plasmacytoid dendritic cells ameliorate experimental chronic kidney disease.

Authors:  Dong Zheng; Qi Cao; Vincent W S Lee; Ya Wang; Guoping Zheng; YuanMin Wang; Thian Kui Tan; Changqi Wang; Stephen I Alexander; David C H Harris; Yiping Wang
Journal:  Kidney Int       Date:  2012-02-08       Impact factor: 10.612

Review 7.  Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Igor A Sobenin; Yuri V Bobryshev
Journal:  Front Physiol       Date:  2014-07-25       Impact factor: 4.566

8.  The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.

Authors:  Yan-Fang Gao; Rui-Qing Peng; Jiang Li; Ya Ding; Xing Zhang; Xiao-Jun Wu; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-08-20       Impact factor: 5.531

9.  The role of indoleamine 2,3-dioxygenase in LP-BPM5 murine retroviral disease progression.

Authors:  Megan A O'Connor; William R Green
Journal:  Virol J       Date:  2013-05-17       Impact factor: 4.099

Review 10.  Immune heterogeneity in neuroinflammation: dendritic cells in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.